GlassScriptPhysician profile
Richard O Buck
NPI 1730166828
$501.40
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $223.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $220.05 | 2019-2020 | |
| Glaxosmithkline, LLC. | $76.70 | 2019-2020 | |
| Octapharma USA, INC. | $74.65 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.20 | 2020 | |
| Csl Behring | $25.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.22 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.00 | 2019 | |
| Pharming Healthcare, INC. | $14.65 | 2019 | |
| Shire North American Group INC | $14.11 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.70 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.